4Chinese Society of Gastroenterology, Chinese Medical Association. Suggested guidelines for the diagnosis and treatment of inflammatory bowel disease[ J ]. Chin J Dig Dis ,2001,2(4) :202 -208.
6Irvine EJ, Greenberg CR, Feagan BG, et al. Quality of life rapidly improves with budesonde theraphy for active Crohn's disease[ J]. Infamm Bowel Dis,2000,6 : 181 - 187.
7Sandbom WJ, Hanauer SB. Infliximab in the treatment of Crohn' s disease:a user' s guide for clinicians [ J]. Am J Gastroenterol, 2002,97:2962 - 2972.
8Chung ES, Packer M, Lo KH, et al. Random ized, double -blind, placebo- controlled, pilot trial of Infiixim ab, a chimeric monoclonal antibody to tumor necrosis factor alpha, in patientswith m oderate - to severe heart failure: results of the anti TNF therapy against congestive heart failure ( ATTACH ) trial Circulation, 2003, 107:3133 -3140.
5Cuffari C,Darbari A.Inflammatory bowel disease in the pediatric and adolescent patient.Gastroenterol Clin North Am,2002,8:145-151.
6Seidman EG.Recent advantances in the diagnosis and treatment of pediatric inflammatory bowel disease.Curr Gastroenterol Rep,2000,2:248-252.
7IBD Working Group of the European Society for Paediatric Gastroenterology,Hepatology and Nutrition.Inflammatory bowel disease in children and adolescents:recommendations for diagnosis-the Porto criteria.J Pediatr Gastroenterol Nutr,2005,41:1-7.
8Mamula P,Mascarenhas MR,Baldassano RN,et al.Biological and novel therapies for inflammatory bowel diasease in children.Pediatr Chin North Am,2002,49:1-25.
9Friesen CA,Calabro C,Christenson K,et al.Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.J Pediatr Gastroenterol Nutr,2004,39:265-269.
10Beaugerie L, Seksik P, Nion-larmurier I, et al. Predictors of Crohn's disease[J]. Gastroenterol, 2006,130(3):650-656.
